In the pipeline: Brentuximab vedotin (SGN-35)

Treadle header

Today's featured lymphoma treatment in the pipeline is the antibody drug conjugate brentuximab vedotin.


Name: Brentuximab vedotin
Class: Antibody drug conjugate (ADC)
Type: Targeted treatment
FDA to date: In Phase II/III trials. FDA approval expected in late 2011.
Manufacturer: Seattle Genetics
Indications: Hodgkin lymphoma, anaplastic large T-cell (non-Hodgkin) lymphoma


A few words: Brentuximab vedotin is arguably generating more hype and excitement than any other lymphoma treatment in the pipeline right now. it is riding the high of outstanding press following very positive data against both Hodgkin's and ALCL reported at the 2010 American Society of Hematology meeting in December. Most expect Seattle Genetics to receive FDA approval for the treatment sometime in 2011.

Brentuximab vedotin brings together an anti-CD30 monoclonal antibody and the synthetic antimicrotubule agent monomethyl auristatin E (MMAE). Once in the body, the monoclonal antibody acts as a targeting system, seeking out cancer cells and delivering its cytotoxic payload (MMAE) into the malignant cell. Efficacy appears very high with a relatively low toxicity profile.

By Ross Bonander

Click here to see clinical trials involving brentuximab vedotin.

LymphomaInfo Social